Advanced in Ovarian Cancer

Yunong L. Gao

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Advanced in Ovarian Cancer
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Yunong Gao practices in Beijing, China. Gao is rated as an Advanced expert by MediFind in the treatment of Ovarian Cancer. Their top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Hysterectomy, and Oophorectomy.

Their clinical research consists of co-authoring 48 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 24 articles and participated in 3 clinical trials in the study of Ovarian Cancer.

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2026
Intervention Type: Drug
Study Drug: Pamiparib
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Pamiparib
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

48 Total Publications

Multigene germline and somatic testing for epithelial ovarian cancer in China.
Multigene germline and somatic testing for epithelial ovarian cancer in China.
Journal: NPJ precision oncology
Published: April 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gao's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile